The shingles vaccine may do more than prevent a painful rash — new research links it to a notably lower risk of vascular dementia and several cardiovascular complications, plus reduced death rates, in older adults. A large U.S. study tracked vaccinated and unvaccinated people over years and found consistent protective associations across multiple serious outcomes. While the results are promising, scientists urge careful interpretation and more research to probe cause and effect.
Researchers from Case Western Reserve University analyzed health records covering 174,000 adults and tracked outcomes from as little as three months up to seven years after vaccination. The findings were presented at IDWEEK 2025 in Atlanta, where infectious disease experts gathered to compare emerging evidence. The study focused on people aged 50 and older, a group already targeted by vaccine recommendations.
Those who received the shingles vaccine showed about half the risk of developing vascular dementia compared with unvaccinated peers, a striking difference in a condition with limited prevention strategies. The vaccinated group also had a roughly 25% lower risk of heart attack or stroke, a 27% lower risk of blood clots, and about a 21% lower risk of death during the follow-up period. These consistent signal patterns across different outcomes suggest a relationship worth investigating further.
“Our study findings show that the shingles vaccine may help lower those risks, especially in people already at higher risk for heart attack or stroke,” said Ali Dehghani, a doctor of internal medicine at Case Western Reserve University’s School of Medicine. That plain statement from the presenting author underscores why clinicians and researchers are paying attention to vaccines beyond their immediate targets. It raises practical questions for doctors counseling older patients about prevention options.
Shingles itself is caused by reactivation of the varicella zoster virus, the same virus that causes chicken pox, and it typically appears as a red, blistering, painful rash. After a childhood chicken pox infection, the virus can lie dormant for decades and then reactivate later in life, sometimes producing serious complications. Past research has linked shingles episodes to an increased chance of cardiovascular and neurologic problems, which makes the idea of prevention particularly appealing.
About one in three Americans will experience shingles at some point, and the vast majority of people born before 1980 were exposed to chicken pox as children. That background prevalence means even modest benefits from vaccination could affect a lot of people. Preventing shingles itself remains the primary goal, but these broader associations hint at secondary gains worth exploring.
“This very interesting study … supported prior evidence that the shingles vaccine may offer several benefits for general health, including against the development of dementia, in addition to preventing the very painful and common illness know as shingles,” said Dr. Aaron Glatt, a spokesperson for the IDSA and a board-certified infectious disease physician. Even with that praise, Glatt and others stress that association does not equal proof of cause and effect, and confounding factors could explain some of the observed differences.
Possible biological explanations include reduced chronic inflammation, fewer viral reactivations that could damage blood vessels or brain tissue, or healthier people being more likely to get vaccinated in the first place. Experts are clear that additional studies are needed to untangle these possibilities and to test whether vaccination directly lowers dementia and cardiovascular risks. “It is very comforting to know that the shingles vaccine is certainly associated with overall significant health benefits beyond its intended purpose.”
Current prevention guidance from public health authorities recommends two doses of the recombinant zoster vaccine for adults aged 50 and older, and for adults 19 and older who are or will be immunodeficient or immunosuppressed. Clinicians and patients weighing vaccine decisions should consider this emerging evidence alongside established benefits in preventing the intense pain and complications of shingles. As researchers pursue deeper answers, the takeaway for many older adults may be that vaccination carries potential upside well past preventing a single disease.
